Anti-SARS-CoV-2 antibodies were detected in the blood of 181 patients (48%) after initial vaccination with one of three U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccines, and patients with active cancer or those recently treated with an immune cell-depleting therapy were least likely to produce these antibodies.

COVID-19 Vaccine Efficacy and Blood Cancer

Among patients who did not mount an antibody response following initial vaccination, responses were observed after a booster dose in 48 of 85 (56%) patients who were assessed.

Advertisement

By the end of February 2022, 33 patients (8.8%) developed a COVID-19 infection, with three COVID-19-related deaths (0.8%).

Although there was no significant link between post-vaccination antibody response and incidence of COVID-19 infection, no patient with antibody responses died from COVID-19.

Also, no patient who received tixagevimab plus cilgavimab was diagnosed with a COVID-19 infection. Tixagevimab and cilgavimab are antibody therapies that bind to non-overlapping portions of the SARS-CoV-2 spike protein, preventing the virus from binding to and infecting cells.

The FDA authorized the combination therapy for emergency use during the COVID-19 pandemic as a way to help prevent COVID-19 infection in certain individuals. These findings build on the wealth of literature showing that patients with hematologic malignancies have an impaired response to COVID vaccination.

This study also suggests to us the importance of checking antibody levels in these patients and arranging prophylactic antibody therapy. It also encourages providing booster vaccines for patients and prioritizing prophylactic antibody therapy when indicated.

This is real-world evidence that these actions can save lives.

Source: Medindia